$-0.14
(Market cap
$586 Mln
Revenue (TTM)
$117 Mln
P/E Ratio
--
P/B Ratio
47.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-9.9
-
Debt to Equity
0
-
Book Value
$0.1
-
EPS
$-2.2
-
Face value
--
-
Shares outstanding
99,447,343
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ARS Pharmaceuticals
| -49.4 | 2.3 | -30.7 | -56.2 | -5.3 | -24.9 | -- |
|
BSE Sensex*
| -8.9 | -1.0 | 3.1 | -3.4 | 5.8 | 6.3 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
ARS Pharmaceuticals
| -85.6 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ARS Pharmaceuticals
|
5.9 | 585.7 | 116.9 | -215.4 | -180.1 | -339.9 | -- | 47.8 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal... delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. Read more
-
Founder, President, CEO & Director
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
-
Founder, President, CEO & Director
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ARS Pharmaceuticals
What is the current share price of ARS Pharmaceuticals, Inc Today?
The share price of ARS Pharmaceuticals, Inc is $5.89 (NASDAQ) as of 28-Aug-2026 16:00 EDT. ARS Pharmaceuticals, Inc has given a return of -5.32% in the last 3 years.
What is the current PB & PE ratio of ARS Pharmaceuticals, Inc?
Since, TTM earnings of ARS Pharmaceuticals, Inc is negative, P/E ratio is not available.
The P/B ratio of ARS Pharmaceuticals, Inc is 47.85 times as on 28-Aug-2026, a 824 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.70 |
10.05 |
2024 |
129.21 |
4.02 |
2023 |
-9.69 |
2.28 |
2022 |
-23.12 |
2.94 |
2021 |
-11.53 |
-7.46 |
What is the 52 Week High and Low of ARS Pharmaceuticals, Inc?
The 52-week high and low of ARS Pharmaceuticals, Inc are Rs 13.46 and Rs 4.91 as of 31-Aug-2026.
What is the market cap of ARS Pharmaceuticals, Inc?
ARS Pharmaceuticals, Inc has a market capitalisation of $ 586 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in ARS Pharmaceuticals, Inc?
Before investing in ARS Pharmaceuticals, Inc, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.